Yucheng Sheng

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 16

Top Topics

Randomized Controlled Trial

Catheter Ablation

Small Cell Lung Cancer

Top Venues

CPT: pharmacometrics & systems pharmacology

Archives of disease in childhood

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Shu-Wen Teng, Yu-Cheng Su, Ravikumar Pallantla, Madhav Channavazzala, Rukmini Kumar, Yucheng Sheng, Hao Wang, Crystal Wang, Archie Tse
Can a Propensity Score Matching Method be Applied to Assessing Efficacy from Single-Arm Proof-of-Concept Trials in Oncology? CPT: pharmacometrics & systems pharmacology (2023)
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse
Tumor Growth Inhibition-Overall Survival Modeling in Non-Small Cell Lung Cancer: A Case Study from GEMSTONE-302. CPT: pharmacometrics & systems pharmacology (2023)
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302. CPT: pharmacometrics & systems pharmacology (2023)
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Sandra Walsh, Shan Pan, Yucheng Sheng, Frank Kloprogge, Joe F Standing, Brian J Anderson, Padmanabhan Ramnarayan, null null
Optimising intravenous salbutamol in children: a phase 2 study. Archives of disease in childhood (2022)
Samuel Orubu, Richard A Kendall, Yucheng Sheng, Catherine Tuleu
Evaluating the Taste Masking Ability of Two Novel Dispersible Tablet Platforms Containing Zinc Sulfate and Paracetamol Reconstituted in a Breast Milk Substitute. Pharmaceutics 14 (2) (2022)
Sandra Walsh, Shan Pan, Yucheng Sheng, Frank Kloprogge, Joe F Standing, Brian J Anderson, Padmanabhan Ramnarayan, null null
Optimising intravenous salbutamol in children: a phase 2 study. Archives of disease in childhood 108 (4) (2022)
Sandra Walsh, Shan Pan, Yucheng Sheng, Frank Kloprogge, Joe F Standing, Brian J Anderson, Padmanabhan Ramnarayan, null null
Optimising intravenous salbutamol in children: a phase 2 study. Archives of disease in childhood 108 (4) (2022)
Sandra Walsh, Shan Pan, Yucheng Sheng, Frank Kloprogge, Joe F Standing, Brian J Anderson, Padmanabhan Ramnarayan, null null
Optimising intravenous salbutamol in children: a phase 2 study. Archives of disease in childhood 108 (4) (2022)
Sandra Walsh, Shan Pan, Yucheng Sheng, Frank Kloprogge, Joe F Standing, Brian J Anderson, Padmanabhan Ramnarayan, null null
Optimising intravenous salbutamol in children: a phase 2 study. Archives of disease in childhood 108 (4) (2022)
Sandra Walsh, Shan Pan, Yucheng Sheng, Frank Kloprogge, Joe F Standing, Brian J Anderson, Padmanabhan Ramnarayan, null null
Optimising intravenous salbutamol in children: a phase 2 study. Archives of disease in childhood (2022)
Yucheng Sheng, Xuan Zhou, Shuying Yang, Peiming Ma, Chao Chen
Modelling item scores of Unified Parkinson's Disease Rating Scale Part III for greater trial efficiency. British journal of clinical pharmacology 87 (9) (2021)